Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis

Ren, Rong; Yin, Pengpeng; Zhang, Yan; Zhou, Jianyun; Zhou, Yixing; Xu, Rufu; Lin, Hai; Huang, Chunji

doi:10.18632/oncotarget.12707

Cited by 31 publications

(31 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We reported non-signi cant difference in the diagnostic validities of survivin and bulin-3 in diagnosing lung cancer or predicting MPM. Although no published data regarding the utility of survivin in diagnosing lung cancer, humoral bulin-3 test data published revealed high variability among studies and still remains a contentious issue (38). A meta-analysis study reported that blood bulin-3 is useful for MPM diagnosis and its validity was higher than soluble mesothelinrelated peptides (SMRP) and osteopontin (38).…”

Section: Discussionmentioning

confidence: 99%

“…Although no published data regarding the utility of survivin in diagnosing lung cancer, humoral bulin-3 test data published revealed high variability among studies and still remains a contentious issue (38). A meta-analysis study reported that blood bulin-3 is useful for MPM diagnosis and its validity was higher than soluble mesothelinrelated peptides (SMRP) and osteopontin (38). Few studies could be traced in literature and reported similar ndings (37,39).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating and Local Nuclear Expression of Survivin and Fibulin-3 Genes in Discriminating Benign From Malignant Respiratory Diseases: Correlation Analysis

Hassan

Abuhamdah

Abdel-Bary

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Survivin is a common member of the inhibitors of the apoptosis protein (IAP) family and promoter of cell proliferation. Fibulin-3 is a matrix glycoprotein with a potential for tumor suppression or propagation. The aim of this study was to validate the expression levels of survivin and fibulin-3 in benign and malignant respiratory diseases.Methods: This case-control study included 219 patients categorized into 5 groups. Group A included 63 patients with lung cancer, group B included 63 patients with various benign lung diseases, group D included 45 patients with malignant pleural mesothelioma (MPM) and group E included 48 patients with various benign pleural diseases. Group C included 60 healthy individuals (control group). Serum survivin and fibulin-3 levels were measured using ELISA assay kits, while their nuclear expression in the lung and pleura was assessed using western blot analysis. Data entry and data analysis are done using SPSS version 19. The Medcalc Program was used to calculate sensitivity, specificity and positive and negative predictive values with calculation of the AUC (95% CI). Results: The overall results showed significantly higher survivin serum levels with significantly lower fibulin-3 levels among group A when compared with both patients in group B and the controls (p<0.001 for all). There were statistically significant higher serum levels of survivin and fibulin-3 among group D when compared with both patients in group E and the controls (p<0.001 for all). These findings were consistent with nuclear survivin and fibulin-3 expression levels. Fibulin-3 was more valid than survivin in discriminating lung cancer from MPM (p˂0.05). Conclusions: Survivin and fibulin-3 could be helpful diagnostic markers for lung and pleural cancers. Fibulin-3 was more specific in differentiating lung cancer from MPM.Trial registration: ClinicalTrials.gov Identifier: NCT04413292: https://clinicaltrials.gov/ct2/show/NCT04413292, retrospectively registered.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Circulating and Local Nuclear Expression of Survivin and Fibulin-3 Genes in Discriminating Benign From Malignant Respiratory Diseases: Correlation Analysis

Hassan

Abuhamdah

Abdel-Bary

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…They found that the overall sensitivity and specificity for blood fibulin-3 were 0.87 [95% confidence interval (CI) 0.58-0.97] and 0.89 (95% CI 0.77-0.95), respectively. Based on these results, they concluded that fibulin-3 is a useful diagnostic biomarker for MM [47]. Similarly, Pei et al reported that fibulin-3 confers a relatively high diagnostic efficacy and could be acceptable as an auxiliary biomarker to aid in MM identification [32].…”

Section: Fibulinmentioning

confidence: 93%

Asbestos-Related Diseases and Blood Biomarkers

Franko¹,

Dolžan²,

Goričar³

et al. 2020

Asbestos-Related Diseases

View full text Add to dashboard Cite

Asbestos-related diseases, including asbestosis, benign pleural diseases, lung cancer, other types of cancer, and especially malignant mesothelioma (MM), still represent an enormous problem all over the world and are among the most investigated occupational diseases. Considering that MM is a highly aggressive and severe malignant cancer of pleura, peritoneum and other serosal surfaces, new blood biomarkers for earlier diagnosis, following response to treatment and disease progression, have been intensively investigated. Several studies suggested that soluble mesothelin-related peptides, fibulin-3, survivin, osteopontin, vimentin, calretinin, and many others could be helpful in diagnosis, detecting the progression of MM and evaluating tumour response to treatment; however, these biomarkers have not been validated in clinical practice. Therefore, search for novel better stand-alone or composite biomarkers is under way. The aim of this chapter is to present the importance of blood biomarkers in evaluating the risk of developing asbestos-related diseases, early diagnosis, following the response to treatment and progression of these diseases, with special emphasis on MM.

show abstract

“…Several studies have investigated the diagnostic value of fibulin-3 for MPM and based on these fibulin-3 results a useful diagnostic marker for MPM (30)(31)(32)(33)(34).…”

Section: Fibulin-3mentioning

confidence: 99%

Serum mesothelin and other biomarkers: what have we learned in the last decade?

et al. 2018

View full text Add to dashboard Cite

In the last decade there is been much interest in noninvasive, economic and well-accepted diagnostic tests for screening of subjects exposed to asbestos, and in patients with malignant pleuric mesothelioma (MPM) for diagnosis or monitoring response to treatment. Several biomarkers have been suggested as tools for screening and early diagnosis of MPM. Currently, in patients with MPM, have been reported high levels of soluble mesothelin-related peptides (SMRP), plasmatic osteopontin (pOPN), vimentin, fibulin-3 and many others as promising marker for diagnosis, even their use in prevention monitoring is still discussed. In this type of disease, a key role could be played by miRNAs, which expression has been investigated in a large series of MPM to examine new pathways useful in diagnosis, prognosis and therapy. An altered expression of some proteins has been reported, useful as biomarkers, in comparative proteomic analysis of malignant pleural mesothelioma. New promising markers are nowadays under study and alone or better in combination, they'll be very helpful in diagnosing, monitoring mesothelioma patients or for screening of risk groups.

show abstract

Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis

Cited by 31 publications

References 48 publications

Circulating and Local Nuclear Expression of Survivin and Fibulin-3 Genes in Discriminating Benign From Malignant Respiratory Diseases: Correlation Analysis

Circulating and Local Nuclear Expression of Survivin and Fibulin-3 Genes in Discriminating Benign From Malignant Respiratory Diseases: Correlation Analysis

Asbestos-Related Diseases and Blood Biomarkers

Serum mesothelin and other biomarkers: what have we learned in the last decade?

Contact Info

Product

Resources

About